Daily Cardiology Research Analysis
Three impactful cardiology studies stood out: a meta-analysis of randomized trials shows SGLT2 inhibitors reduce sudden cardiac death; a multinational cohort analysis links changes in depressive symptoms to incident cardiovascular disease risk; and an ARIC cohort analysis introduces LDL cholesterol ‘time in target range’ as a powerful predictor of cardiovascular outcomes. Together, they emphasize therapy choice, mental health dynamics, and longitudinal lipid control as actionable levers for prev
Summary
Three impactful cardiology studies stood out: a meta-analysis of randomized trials shows SGLT2 inhibitors reduce sudden cardiac death; a multinational cohort analysis links changes in depressive symptoms to incident cardiovascular disease risk; and an ARIC cohort analysis introduces LDL cholesterol ‘time in target range’ as a powerful predictor of cardiovascular outcomes. Together, they emphasize therapy choice, mental health dynamics, and longitudinal lipid control as actionable levers for prevention.
Research Themes
- Cardiometabolic therapy and arrhythmic mortality
- Psychosocial risk dynamics in cardiovascular disease
- Longitudinal lipid control metrics for risk prediction
Selected Articles
1. Impact of empagliflozin and dapagliflozin on sudden cardiac death: A systematic review and meta-analysis of adjudicated randomized evidence.
In a meta-analysis of 8 randomized trials (n=58,569), SGLT2 inhibitors reduced adjudicated sudden cardiac death by 18% with minimal heterogeneity. Benefits were consistent across cardio-renal-metabolic populations, supporting an anti-arrhythmic clinical effect beyond known heart failure and kidney benefits.
Impact: This adjudicated RCT meta-analysis addresses a major unresolved question—whether SGLT2 inhibitors lower sudden death—providing higher-level evidence with direct practice implications.
Clinical Implications: When selecting cardiometabolic therapy in T2D, HF, or CKD, consider SGLT2 inhibitors for potential reduction in sudden cardiac death, especially in patients at high arrhythmic risk; this complements but does not replace ICD indications or guideline-directed HF therapy.
Key Findings
- Across 8 randomized trials (n=58,569), SGLT2 inhibitors reduced sudden cardiac death (OR 0.82; 95% CI 0.72–0.94; P=0.0104).
- Median follow-up was 29 months, and heterogeneity was negligible, supporting robustness.
- Benefits were observed across populations with T2D, heart failure, or chronic kidney disease, suggesting a class effect.
Methodological Strengths
- Pooled adjudicated endpoints from randomized controlled trials with large total sample size.
- Meta-regression and subgroup analyses with minimal heterogeneity.
Limitations
- Specific subgroup effect sizes and trial-level variations are not fully detailed in the abstract.
- Mechanistic drivers of SCD reduction were not directly assessed.
Future Directions: Trials with pre-specified arrhythmic endpoints and rhythm monitoring should confirm and dissect mechanisms; identify phenotypes with maximal SCD benefit.
BACKGROUND: Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce cardiovascular outcomes in the spectrum of cardio-renal-metabolic syndrome. Albeit basic and translational evidence support a putative anti-arrhythmic role, at the clinical level, a lack of consensus has emerged across different studies, and the true impact on sudden cardiac death (SCD) risk remains unclear. OBJECTIVE: The study aimed to assess the effect of empagliflozin and dapagliflozin on SCD in patients with type 2 diabetes, heart failure, or chronic kidney disease. METHODS: A systematic review and meta-analysis were conducted on randomized controlled trials. A total of 58,569 participants from 8 trials were included, with 30,565 patients treated with SGLT2 inhibitors and 28,104 controls assigned to placebo. The median follow-up period was 29 months. We performed pooled analysis, meta-regression, and subgroup analyses to explore the impact on SCD risk across different populations and treatment regimens. RESULTS: The pooled analysis showed a reduced risk of SCD with SGLT2 inhibitors (odds ratio: 0.82; 95% confidence interval: 0.72-0.94; P = .0104), with negligible heterogeneity (τ
2. Changes in depressive symptoms as predictors of incident cardiovascular disease: insights from four prospective cohorts.
Harmonized analyses across four prospective cohorts (n=33,437) show that worsening depressive symptoms increase incident CVD risk, whereas improvement or remission confers graded risk reductions. A clear dose–response was observed for both total depression scores and their changes, with stronger effects under age 65.
Impact: By focusing on symptom dynamics rather than static status, this study identifies modifiable mental health trajectories as potent predictors of CVD, informing prevention strategies.
Clinical Implications: Incorporate repeated depression screening and treat-to-remission strategies into CVD prevention, particularly in midlife adults; integrate mental health changes into cardiovascular risk assessments.
Key Findings
- Progression from no depression to mild or moderate–severe increased CVD risk by 28% and 23%, respectively.
- Remission from mild to none reduced CVD risk by 19%; from moderate–severe to mild by 25%; to none by 38%.
- Each 1-unit increase in total depression score raised CVD risk by 12%, and each 1-unit increase in score change increased risk by 15%; effects were stronger in participants <65 years.
Methodological Strengths
- Harmonized multi-country prospective cohorts with standardized depression metrics.
- Dose–response analyses using both absolute scores and score changes with Cox modeling.
Limitations
- Follow-up duration and event adjudication details vary across cohorts and are not specified in the abstract.
- Residual confounding from unmeasured psychosocial or clinical factors is possible.
Future Directions: Interventional trials testing depression treatment-to-remission for CVD risk reduction; integration of mental health trajectories into risk calculators.
AIMS: This study examines how changes in depressive symptoms influence cardiovascular disease (CVD) incidence in diverse aging populations. METHODS AND RESULTS: Data from four longitudinal cohorts were harmonized: CHARLS (China), ELSA (UK), HRS (US), and MHAS (Mexico). Depressive symptoms were assessed at baseline and follow-up using validated scales, and scores were standardized using z-scores. The primary outcome was incident CVD, defined as a composite of heart attack, angina, congestive heart failure, other physician-diagnosed heart conditions, and stroke. Cox proportional regression analyses assessed the associations between changes in depressive symptoms and CVD risk. Progression from no depression to mild depression was associated with a 28% increase in CVD risk (95% CI: 1.14-1.44), while progression to moderate-to-severe depression was associated with a 23% increase (95% CI: 1.04-1.46). Conversely, remission from mild depression to no depression significantly reduced CVD risk by 19% (95% CI: 0.68-0.98). Improvement from moderate-to-severe depression to mild depression decreased CVD risk by 25% (95% CI: 0.61-0.93), and remission from moderate-to-severe depression to no depression reduced it by 38% (95% CI: 0.50-0.76). Each 1-unit increase in the total depression score raised CVD risk by 12% (95% CI: 1.10-1.14), while each 1-unit increase in depression score change increased risk by 15% (95% CI: 1.11-1.19). Effects were stronger in participants aged <65 years than participants aged ≥65 years. CONCLUSION: This multinational cohort study demonstrates that worsening or progression of depressive symptoms increases CVD risk, while remission or improvement confers protective effects, highlighting the need to monitor depression symptom changes in CVD prevention. This multinational longitudinal study investigated how changes in depressive symptoms influence the risk of incident CVD across four aging populations from diverse regions (China, UK, US, and Mexico). Utilizing harmonized data from four prospective cohort studies (CHARLS, ELSA, HRS, MHAS; N = 33,437), we found significant associations between depressive symptom changes and CVD incidence. Key findings revealed that: (1) Progression or worsening of depressive symptoms increased CVD risk: progression from no depression to mild depression increased CVD risk by 28% (95% CI: 1.14-1.44), while progression to moderate-to-severe depression raised CVD risk by 23% (95% CI: 1.04-1.46); (2) Improvement or remission of depressive symptoms reduced CVD risk: remission from mild depression to no depression significantly reduced CVD risk by 19% (95% CI: 0.68-0.98); improvement from moderate-to-severe depression to mild depression decreased CVD risk by 25% (95% CI: 0.61-0.93), and remission from moderate-to-severe depression to no depression reduced it by 38% (95% CI: 0.50-0.76). Furthermore, continuous measures demonstrated a robust dose-response relationship, with each 1-unit increase in the total depression score raised CVD risk by 12% (95% CI: 1.10-1.14), while each 1-unit increase in depressive symptom change increased risk by 15% (95% CI: 1.11-1.19). These findings highlight the importance of monitoring depressive symptoms in CVD prevention, and suggest that interventions targeting depressive symptoms may benefit cardiovascular health.
3. Low-Density Lipoprotein Cholesterol Time in Target Range and Clinical Outcomes in the General Population.
In 8,813 ARIC participants with serial LDL-C measures, greater LDL-C time in target range was associated with substantially lower risks of MI, composite CVD, HF, and stroke over a median 6.2 years. Incorporating LDL-C TTR improved risk prediction beyond traditional models.
Impact: Introduces a pragmatic longitudinal metric (LDL-C TTR) that better captures lipid control quality and predicts diverse cardiovascular outcomes, offering a target for quality improvement.
Clinical Implications: Monitor and optimize LDL-C TTR, not just single measurements; use TTR to guide therapy intensification, adherence interventions, and to refine risk stratification.
Key Findings
- Compared with LDL-C TTR 0–25%, TTR 75–100% was associated with 33% lower MI risk, 34% lower CVD risk, 15% lower HF risk, and 24% lower stroke risk.
- Median follow-up was 6.2 years with substantial event counts across outcomes.
- Adding LDL-C TTR significantly improved prediction metrics (C-statistics, NRI, IDI) for MI and CVD.
Methodological Strengths
- Large community-based cohort with serial LDL-C measures enabling longitudinal exposure modeling.
- Robust multivariable Cox, competing risk, and 10-year landmark analyses with multiple outcomes.
Limitations
- Observational design may be affected by residual confounding (e.g., adherence, treatment changes).
- Generalizability beyond ARIC demographics requires caution.
Future Directions: Test TTR-guided lipid management strategies in pragmatic trials; evaluate TTR integration into clinical decision support and quality metrics.
BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) is a well-established cardiovascular risk predictor. However, it remains unclear whether the changes in LDL-C over time characterized by time in target range (TTR) are associated with adverse clinical outcomes. OBJECTIVES: This study aimed to investigate the association between LDL-C TTR and adverse outcomes in the general population. METHODS: In 8,813 ARIC (Atherosclerosis Risk In Communities) study participants with ≥2 LDL-C measures between the first (1987-1989) and fifth (2011-2013) visits, LDL-C TTR was defined as <70 mg/dL or <130 mg/dL for participants with or without prevalent atherosclerotic cardiovascular disease (CVD). Multivariable Cox models, competitive risk analysis, and a 10-year landmark analysis were used to estimate the association of LDL-C TTR with myocardial infarction (MI), CVDs, heart failure (HF), and stroke. RESULTS: Over 6.2 years (median), 1,010 participants experienced MI, 1,308 participants experienced CVD, 1,863 participants experienced HF, and 753 participants experienced stroke. In multivariable-adjusted analyses, compared with participants with LDL-C TTR of 0% to 25%, those with LDL-C TTR of 75% to 100% had 33.2% lower risk of MI (HR: 0.668; 95% CI: 0.539-0.829), 33.8% for CVD (HR: 0.662; 95% CI: 0.548-0.799), 15.3% for HF (HR: 0.847; 95% CI: 0.729-0.984), and 23.7% for stroke (HR: 0.763; 95% CI: 0.603-0.964). Adding LDL-C TTR to a conventional risk model significantly improved risk prediction (P < 0.001) assessed by C statistics, net reclassification improvement, and integrated discrimination improvement for MI (0.70, 33.95%, and 1.01%) and for CVD (0.71, 35.42%, and 1.30%). CONCLUSIONS: In the general population, higher LDL-C TTR was significantly associated with lower risks of adverse clinical outcomes.